However, no statistically significant differenceswere detected in our analysis of hypertension incidence between the three agents.It is still unclear whether such inflammation is due to malignancy ordrug-induced cardiotoxicity in cancer patients taking CDK4/6 inhibitors [20, 37].Specific biomarkers associated with vascular inflammation in patients receivingCDK4/6 inhibitors have not been identified [38]. Here, CDK4 is linked to hypertensive disorder.